cox 189 has been researched along with Cholera Infantum in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Branson, J; Ford, M; Kellett, N; Mair, S; Milosavljev, S; Rordorf, C; Scott, G | 1 |
| Mysler, E | 1 |
| Goldstein, JL; Rosenberg, JA | 1 |
| Gitton, X; Hawkey, CJ; Hoexter, G; Richard, D; Weinstein, WM | 1 |
| Hawkey, CJ; Krammer, G; Murphy, V; Rebuli, R; Richard, D; Stricker, K; Weinstein, WM | 1 |
| Fleischmann, R; Notter, M; Patel, NP; Reginster, JY; Sallstig, P; Tannenbaum, H | 1 |
2 review(s) available for cox 189 and Cholera Infantum
| Article | Year |
|---|---|
Lumiracoxib (Prexige): a new selective COX-2 inhibitor.
Topics: Acute Disease; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Evaluation; Drug Interactions; Gastrointestinal Diseases; Humans; Isoenzymes; Membrane Proteins; Organic Chemicals; Pain; Prostaglandin-Endoperoxide Synthases | 2004 |
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Organic Chemicals; Osteoarthritis; Randomized Controlled Trials as Topic | 2006 |
4 trial(s) available for cox 189 and Cholera Infantum
| Article | Year |
|---|---|
Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects.
Topics: Adolescent; Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Endoscopy, Gastrointestinal; Gastrointestinal Diseases; Humans; Intestinal Mucosa; Isoenzymes; Male; Membrane Proteins; Middle Aged; Naproxen; Organic Chemicals; Pilot Projects; Prostaglandin-Endoperoxide Synthases; Thromboxanes | 2003 |
Safety and efficacy of lumiracoxib compared with NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Diseases; Humans; Incidence; Organic Chemicals; Osteoarthritis; Risk Factors; Time Factors; Treatment Outcome | 2005 |
Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Even
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Cyclooxygenase 2 Inhibitors; Diclofenac; Female; Gastrointestinal Diseases; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Statistics as Topic | 2008 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Drug Administration Schedule; Europe; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis; Pain Measurement; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome; United States | 2008 |